Sugammadex + Neostigmine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Incomplete Reversal of Neuromuscular Block

Conditions

Incomplete Reversal of Neuromuscular Block

Trial Timeline

Nov 1, 2016 → Feb 1, 2018

NCT ID

NCT02909439

About Sugammadex + Neostigmine

Sugammadex + Neostigmine is a approved stage product being developed by Merck for Incomplete Reversal of Neuromuscular Block. The current trial status is completed. This product is registered under clinical trial identifier NCT02909439. Target conditions include Incomplete Reversal of Neuromuscular Block.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04546672	Approved	Completed	Mar 16, 2021	Aug 13, 2023	Bowel Dysfunction
NCT03276026	Approved	Terminated	Feb 12, 2018	Nov 8, 2018	Postoperative Nausea and Vomiting
NCT03112993	Approved	Completed	May 30, 2017	Aug 14, 2018	Spine Surgery
NCT02861131	Approved	Completed	Jan 24, 2017	Apr 30, 2018	Postoperative Complications
NCT02909439	Approved	Completed	Nov 1, 2016	Feb 1, 2018	Incomplete Reversal of Neuromuscular Block
NCT01050543	Phase 3	Completed	Feb 1, 2010	Aug 20, 2010	Neuromuscular Blockade
NCT00825812	Phase 3	Completed	Jan 1, 2010	Sep 1, 2010	Anesthesia, General
NCT00451217	Phase 3	Completed	Nov 17, 2005	Mar 6, 2006	Anesthesia, General
NCT00451100	Phase 3	Completed	Nov 10, 2005	Aug 29, 2006	Anesthesia, General